AAPL323.81+8.47 (+2.69%) ▲|ABBV252.61+1.70 (+0.68%) ▲|ABT103.82-1.42 (-1.34%) ▼|ACN177.64+1.84 (+1.05%) ▲|ADBE249.37-5.49 (-2.15%) ▼|AMAT457.63-11.22 (-2.39%) ▼|AMD506.42-14.68 (-2.82%) ▼|AMGN382.73-8.54 (-2.18%) ▼|AMT172.86-2.57 (-1.47%) ▼|AMZN252.26-0.15 (-0.06%) ▼|AVGO362.82-1.56 (-0.43%) ▼|AXP320.69-1.12 (-0.35%) ▼|BA206.24-0.18 (-0.09%) ▼|BAC62.40-0.28 (-0.44%) ▼|BKNG175.74+2.31 (+1.33%) ▲|BLK1,069.35-2.69 (-0.25%) ▼|BMY63.95-0.46 (-0.71%) ▼|BNY162.29-0.22 (-0.14%) ▼|BRK-B504.93-1.79 (-0.35%) ▼|C137.99+0.19 (+0.14%) ▲|CAT802.09-13.48 (-1.65%) ▼|CL88.23+0.20 (+0.23%) ▲|CMCSA25.15+0.56 (+2.26%) ▲|COF207.55-3.31 (-1.57%) ▼|COP137.88+1.35 (+0.99%) ▲|COST899.44-3.16 (-0.35%) ▼|CRM244.04-0.12 (-0.05%) ▼|CSCO108.19-1.24 (-1.13%) ▼|CVS95.24-0.14 (-0.15%) ▼|CVX213.52-0.30 (-0.14%) ▼|DE674.07-3.14 (-0.46%) ▼|DHR201.69-3.17 (-1.55%) ▼|DIS104.89+0.71 (+0.68%) ▲|DUK119.64-0.80 (-0.66%) ▼|EMR147.52-2.83 (-1.88%) ▼|FDX311.06+1.87 (+0.60%) ▲|GD353.48+0.81 (+0.23%) ▲|GE322.87-2.55 (-0.78%) ▼|GEV925.75-25.29 (-2.66%) ▼|GILD145.05-0.60 (-0.41%) ▼|GM85.49+1.73 (+2.07%) ▲|GOOG329.31+0.93 (+0.28%) ▲|GOOGL331.57+0.92 (+0.28%) ▲|GS1,020.01-8.77 (-0.85%) ▼|HD305.21-5.24 (-1.69%) ▼|HON202.18-2.76 (-1.34%) ▼|IBM236.33-3.62 (-1.51%) ▼|INTC101.37-4.87 (-4.58%) ▼|INTU312.62-1.32 (-0.42%) ▼|ISRG360.15+6.91 (+1.96%) ▲|JNJ266.75-0.34 (-0.13%) ▼|JPM352.80-1.91 (-0.54%) ▼|KO88.14+0.59 (+0.67%) ▲|LIN461.61-5.05 (-1.08%) ▼|LLY1,126.61+2.40 (+0.21%) ▲|LMT528.21+3.75 (+0.72%) ▲|LOW195.79-2.82 (-1.42%) ▼|LRCX300.79-15.05 (-4.77%) ▼|MA564.19-3.32 (-0.58%) ▼|MCD253.70+0.22 (+0.08%) ▲|MDLZ62.26-0.16 (-0.26%) ▼|MDT91.36-0.53 (-0.58%) ▼|META649.75-3.94 (-0.60%) ▼|MMM162.34-2.06 (-1.25%) ▼|MO68.67+0.78 (+1.14%) ▲|MRK145.04-2.50 (-1.69%) ▼|MS213.84-1.51 (-0.70%) ▼|MSFT492.38+0.73 (+0.15%) ▲|MU979.91-47.87 (-4.66%) ▼|NEE82.55-0.10 (-0.12%) ▼|NFLX75.99-0.05 (-0.06%) ▼|NKE36.81-0.54 (-1.45%) ▼|NOW131.94+0.83 (+0.63%) ▲|NVDA218.46-5.21 (-2.33%) ▼|ORCL156.58-5.05 (-3.12%) ▼|PEP136.89+0.20 (+0.15%) ▲|PFE27.51-0.28 (-0.99%) ▼|PG142.91+0.27 (+0.19%) ▲|PLTR166.14-3.39 (-2.00%) ▼|PM189.15+3.44 (+1.85%) ▲|QCOM180.12+3.72 (+2.11%) ▲|RTX197.41-0.14 (-0.07%) ▼|SBUX99.65-0.39 (-0.39%) ▼|SCHW106.74+0.20 (+0.18%) ▲|SO87.91-0.44 (-0.49%) ▼|SPG205.94+1.41 (+0.69%) ▲|T25.53+0.38 (+1.49%) ▲|TMO603.01-2.68 (-0.44%) ▼|TMUS175.87-1.47 (-0.83%) ▼|TSLA366.60-1.21 (-0.33%) ▼|TXN259.47-2.12 (-0.81%) ▼|UBER72.45+1.37 (+1.93%) ▲|UNH390.92-2.14 (-0.54%) ▼|UNP284.23-0.52 (-0.18%) ▼|UPS100.08+0.86 (+0.86%) ▲|USB62.01-0.11 (-0.17%) ▼|V366.59-0.80 (-0.22%) ▼|VZ49.92+0.18 (+0.36%) ▲|WFC88.94-0.74 (-0.82%) ▼|WMT105.89+0.06 (+0.05%) ▲|XOM165.42+1.19 (+0.72%) ▲|AAPL323.81+8.47 (+2.69%) ▲|ABBV252.61+1.70 (+0.68%) ▲|ABT103.82-1.42 (-1.34%) ▼|ACN177.64+1.84 (+1.05%) ▲|ADBE249.37-5.49 (-2.15%) ▼|AMAT457.63-11.22 (-2.39%) ▼|AMD506.42-14.68 (-2.82%) ▼|AMGN382.73-8.54 (-2.18%) ▼|AMT172.86-2.57 (-1.47%) ▼|AMZN252.26-0.15 (-0.06%) ▼|AVGO362.82-1.56 (-0.43%) ▼|AXP320.69-1.12 (-0.35%) ▼|BA206.24-0.18 (-0.09%) ▼|BAC62.40-0.28 (-0.44%) ▼|BKNG175.74+2.31 (+1.33%) ▲|BLK1,069.35-2.69 (-0.25%) ▼|BMY63.95-0.46 (-0.71%) ▼|BNY162.29-0.22 (-0.14%) ▼|BRK-B504.93-1.79 (-0.35%) ▼|C137.99+0.19 (+0.14%) ▲|CAT802.09-13.48 (-1.65%) ▼|CL88.23+0.20 (+0.23%) ▲|CMCSA25.15+0.56 (+2.26%) ▲|COF207.55-3.31 (-1.57%) ▼|COP137.88+1.35 (+0.99%) ▲|COST899.44-3.16 (-0.35%) ▼|CRM244.04-0.12 (-0.05%) ▼|CSCO108.19-1.24 (-1.13%) ▼|CVS95.24-0.14 (-0.15%) ▼|CVX213.52-0.30 (-0.14%) ▼|DE674.07-3.14 (-0.46%) ▼|DHR201.69-3.17 (-1.55%) ▼|DIS104.89+0.71 (+0.68%) ▲|DUK119.64-0.80 (-0.66%) ▼|EMR147.52-2.83 (-1.88%) ▼|FDX311.06+1.87 (+0.60%) ▲|GD353.48+0.81 (+0.23%) ▲|GE322.87-2.55 (-0.78%) ▼|GEV925.75-25.29 (-2.66%) ▼|GILD145.05-0.60 (-0.41%) ▼|GM85.49+1.73 (+2.07%) ▲|GOOG329.31+0.93 (+0.28%) ▲|GOOGL331.57+0.92 (+0.28%) ▲|GS1,020.01-8.77 (-0.85%) ▼|HD305.21-5.24 (-1.69%) ▼|HON202.18-2.76 (-1.34%) ▼|IBM236.33-3.62 (-1.51%) ▼|INTC101.37-4.87 (-4.58%) ▼|INTU312.62-1.32 (-0.42%) ▼|ISRG360.15+6.91 (+1.96%) ▲|JNJ266.75-0.34 (-0.13%) ▼|JPM352.80-1.91 (-0.54%) ▼|KO88.14+0.59 (+0.67%) ▲|LIN461.61-5.05 (-1.08%) ▼|LLY1,126.61+2.40 (+0.21%) ▲|LMT528.21+3.75 (+0.72%) ▲|LOW195.79-2.82 (-1.42%) ▼|LRCX300.79-15.05 (-4.77%) ▼|MA564.19-3.32 (-0.58%) ▼|MCD253.70+0.22 (+0.08%) ▲|MDLZ62.26-0.16 (-0.26%) ▼|MDT91.36-0.53 (-0.58%) ▼|META649.75-3.94 (-0.60%) ▼|MMM162.34-2.06 (-1.25%) ▼|MO68.67+0.78 (+1.14%) ▲|MRK145.04-2.50 (-1.69%) ▼|MS213.84-1.51 (-0.70%) ▼|MSFT492.38+0.73 (+0.15%) ▲|MU979.91-47.87 (-4.66%) ▼|NEE82.55-0.10 (-0.12%) ▼|NFLX75.99-0.05 (-0.06%) ▼|NKE36.81-0.54 (-1.45%) ▼|NOW131.94+0.83 (+0.63%) ▲|NVDA218.46-5.21 (-2.33%) ▼|ORCL156.58-5.05 (-3.12%) ▼|PEP136.89+0.20 (+0.15%) ▲|PFE27.51-0.28 (-0.99%) ▼|PG142.91+0.27 (+0.19%) ▲|PLTR166.14-3.39 (-2.00%) ▼|PM189.15+3.44 (+1.85%) ▲|QCOM180.12+3.72 (+2.11%) ▲|RTX197.41-0.14 (-0.07%) ▼|SBUX99.65-0.39 (-0.39%) ▼|SCHW106.74+0.20 (+0.18%) ▲|SO87.91-0.44 (-0.49%) ▼|SPG205.94+1.41 (+0.69%) ▲|T25.53+0.38 (+1.49%) ▲|TMO603.01-2.68 (-0.44%) ▼|TMUS175.87-1.47 (-0.83%) ▼|TSLA366.60-1.21 (-0.33%) ▼|TXN259.47-2.12 (-0.81%) ▼|UBER72.45+1.37 (+1.93%) ▲|UNH390.92-2.14 (-0.54%) ▼|UNP284.23-0.52 (-0.18%) ▼|UPS100.08+0.86 (+0.86%) ▲|USB62.01-0.11 (-0.17%) ▼|V366.59-0.80 (-0.22%) ▼|VZ49.92+0.18 (+0.36%) ▲|WFC88.94-0.74 (-0.82%) ▼|WMT105.89+0.06 (+0.05%) ▲|XOM165.42+1.19 (+0.72%) ▲|
27.5 C
New York
Thursday, September 10, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased the securities of Replimune Group, Inc. (NASDAQ: REPL) (“Replimune” or the “Company”)

Amedisys Reports Second Quarter 2025 Financial Results

BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025.

BlueSphere Bio CSO Alan Korman Recipient of Esteemed 2025 William B. Coley Award

Alan Korman honored in the category of tumor immunology for foundational role in checkpoint inhibitors PITTSBURGH, July 29, 2025 /PRNewswire/ -- BlueSphere Bio, a clinical...

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of...

Hansa Biopharma announces key executive appointments to support continued growth

LUND, Sweden, July 29, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Former AdventHealth President & CEO Terry Shaw Joins RAAPID Advisory Board

LOUISVILLE, Ky., July 29, 2025 /PRNewswire/ -- RAAPID, a M12 (Microsoft Venture Fund) backed company and leading AI-powered risk adjustment solutions provider, today announced the...

Monogram Technologies Announces World’s First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery

Monogram Technologies Announces World’s First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery

Beyond Diagnosis: The Real-World Impact of AVISE Testing on Lupus, Rheumatoid Arthritis, and Autoimmune Disease Care, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how advanced autoimmune testing supports diagnostic clarity in early or ambiguous clinical presentations. The featured speakers will review case-based evidence...

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease

Meliodays and Celanese Partner for Meliodays’ Development of Hormone-Free Non-Contraceptive IUD designed to Treat Menstrual Pain

MUNICH, July 29, 2025 (GLOBE NEWSWIRE) -- Meliodays Medical and Celanese Corporation (NYSE: CE) have signed an agreement related to Meliodays’ pre-clinical development of MelioOne®, the first hormone-free non-contraceptive intrauterine device (IUD) designed to deliver localized relief for menstrual pain. MelioOne® combines the proven VitalDose® Drug Delivery Platform from Celanese with Meliodays’ innovative IUD design and non-hormonal active pharmaceutical ingredient (API).

MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy

Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers